The Company is in search of an opportunity to sell to an organization that has the ability to fully commercialize its revolutionary FDA Cleared and CE Marked and patented, single use needle biopsy closure device. The device efficiently seals biopsy channels, enhancing safety for high-risk patients and enabling the use of larger needles for more substantial tissue samples in fewer passes. Its usage may reduce procedure costs by eliminating the need for certain medications, hemostatic agents, and post-procedure observation. Effective channel sealing may also minimize hemorrhage, leading to improved patient outcomes. The device stands out as the only patented electro-cautery device designed to fit biopsy channels, ensuring innovation and effectiveness.
NDA is required to secure comprehensive Confidential Information Memorandum (CIM) crafted by ProNova Partners.
